Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer Feb 3, 2021
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial Jan 13, 2021
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial Jan 6, 2021
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference Jan 5, 2021
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study Nov 19, 2020
Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates Nov 13, 2020
Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study Oct 21, 2020
Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates Sep 21, 2020
Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million Sep 1, 2020
